IDEAYA Biosciences enters license with Hengrui Pharma for a novel phase 1 DLL3 Topo-I-Payload ADC targeting SCLC and NET solid tumors

Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)

Schizophrenia in Children: Understanding Early-Onset Schizophrenia

Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia

Cupid strengthens board with appointment of four new directors

Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director

Reliance acquires Karkinos Healthcare for Rs. 375 Cr

Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.

Shilpa Medicare's Unit IV receives Eurasia GMP approval

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia

Dr. Sandip Shah appointed as Chairperson of NABL-QCI

Venus Remedies partners with NSDC for workforce development through skill certification

Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution

Thyrocare secures NABL accreditation for its Labs

Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation

Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH

Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company

The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities